The treatment of mCRPC with a combination of docetaxel + enzalutamide

We know that both abiraterone acetate (Zytiga) and enzalutamide (Xtandi) can be used to extend the survival of men with mCRPC who have already been treated with docetaxel + prednisone. However, … READ MORE …

PLEASE consider completing our recent survey!

So just over 300 patients have already completed the survey that we put up on line last Friday. Thanks to all of you who have done that. And we’d really like to see if we can get to a total of something like 750 “with a little help from our friends”. … READ MORE …

A new study (and new technology) about quality of life and prostate cancer

Prostate Cancer International and two of its partners — CancerLife and the John Wayne Cancer Institute in Santa Monica, CA — are soon going to be looking for men to participate in a new clinical trial about quality of life and living with prostate cancer. … READ MORE …

Positive outcomes for apalutamide in the treatment of mHSPC

According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …

Is time to biochemical failure a good surrogate endpoint for overall survival?

For many years researchers have been trying to identify so-called “surrogate” endpoints that can be used to predict overall and prostate cancer-specific survival with high accuracy. … READ MORE …

ADT + enzalutamide in mHSPC … outcome of the ARCHES trial

Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

MFS as an endpoint in clinical trials

Earlier this year, two drugs (apalutamide/Erleada and enzalutamide/Xtandi) were each approved for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC) based on the use of metastasis-free survival (MFS) as the study endpoint in clinical trials. … READ MORE …